https://scholars.lib.ntu.edu.tw/handle/123456789/628046
標題: | TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes | 作者: | Yu, Ming-Lung CHIH-YUAN WANG Lee, Mei-Hsuan Ou, Horng-Yih Cheng, Pin-Nan Tu, Shih-Te Huang, Jee-Fu Chen, Jung-Fu Hu, Tsung-Hui Hsu, Chih-Cheng JIA-HORNG KAO Chen, Chien-Jen Lin, Han-Chieh Huang, Chien-Ning |
關鍵字: | Consensus statement; Diabetes mellitus; Direct-acting antivirals; Hepatitis C virus | 公開日期: | 6-二月-2023 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Diabetes mellitus (DM) and hepatitis C virus (HCV) infection are prevalent diseases globally and emerging evidence demonstrates the bidirectional association between the two diseases. Direct-acting antivirals (DAAs) for HCV have a high treatment success rate and can significantly reduce the risks of short and long-term complications of HCV infection. However, despite the evidence of the association between diabetes and HCV and the benefits of anti-HCV treatment, previously published guidelines did not focus on the universal HCV screening for patients with diabetes and their subsequent management once confirmed as having HCV viremia. Nonetheless, screening for HCV among patients with diabetes will contribute to the eradication of HCV infection. Thus, the three major Taiwan medical associations of diabetes and liver diseases endorsed a total of 14 experts in the fields of gastroenterology, hepatology, diabetology, and epidemiology to convene and formulate a consensus statement on HCV screening and management among patients with diabetes. Based on recent studies and guidelines as well as from real-world clinical experiences, the Taiwan experts reached a consensus that provides a straightforward approach to HCV screening, treatment, and monitoring of patients with diabetes. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628046 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2023.01.011 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。